Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma
复制标题
DOI：
10.1016/j.bbmt.2014.06.037
复制
发表时间：
2014-11-01
影响因子：
4.3
通讯作者：
Forman, Stephen J.
中科院分区：
文献类型：
--
作者：
Chen, Robert;Palmer, Joycelynne M.;Forman, Stephen J.
我们之前报道brentuximab vedotin （BV）在中位随访14.4个月后，使复发霍奇金淋巴瘤患者的低强度异基因造血细胞移植（RIC-alloHCT）成功。我们现在提供了一份更新的报告，在中位随访29.9个月后，从2009年到2012年在RIC-alloHCT前接受统一氟达拉滨/美法兰调节方案和供体来源治疗的21例BV患者。我们还回顾性地比较了这些BV治疗前的患者和23名在药物可用之前（2003年至2009年）接受氟达拉滨/美法兰RIC-alloHCT治疗的无BV患者的患者特征和结果。在RIC-alloHCT之前接受BV治疗的患者具有较低的中位造血细胞移植特异性合并症指数和较少的移植周毒性。2年无进展生存率（59.3%对26.1%）和累积复发/进展发生率（23.8%对56.5%）也有改善。(C) 2014年美国血液和骨髓移植学会。
We previously reported that brentuximab vedotin (BV) enabled successful reduced-intensity allogeneic hematopoietic cell transplantation (RIC-alloHCT) in patients with relapsed Hodgkin lymphoma, after a median follow-up of 14.4 months. We now provide an updated report on 21 patients who were treated from 2009 to 2012 with BV before RIC-alloHCT with a uniform fludarabine/melphalan conditioning regimen and donor source after a median follow-up of 29.9 months. We have also retrospectively compared the patient characteristics and outcomes of these BV-pretreated patients to 23 patients who received fludarabine/melphalan RIC-alloHCT without prior BV, in the time period before the drug was available (2003 to 2009). Patients who were treated with BV before RIC-alloHCT had a lower median hematopoietic cell transplantation-specific comorbidity index and a reduced number of peri-transplantation toxicities. There were also improvements in 2-year progression-free survival (59.3% versus 26.1%) and cumulative incidence of relapse/progression (23.8% versus 56.5%). (C) 2014 American Society for Blood and Marrow Transplantation.